Evoke Pharma (EVOK) Stock Forecast, Price Target & Predictions
EVOK Stock Forecast
Evoke Pharma stock forecast is as follows: an average price target of $18.00 (represents a 255.03% upside from EVOK’s last price of $5.07) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
EVOK Price Target
The average price target for Evoke Pharma (EVOK) is $18.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $18.00 to $18.00. This represents a potential 255.03% upside from EVOK's last price of $5.07.
EVOK Analyst Ratings
According to 1 Wall Street analysts, Evoke Pharma's rating consensus is 'Buy'. The analyst rating breakdown for EVOK stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Evoke Pharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 28, 2024 | Yale Jen | Laidlaw | $18.00 | $7.08 | 154.24% | 255.03% |
The latest Evoke Pharma stock forecast, released on Oct 28, 2024 by Yale Jen from Laidlaw, set a price target of $18.00, which represents a 154.24% increase from the stock price at the time of the forecast ($7.08), and a 255.03% increase from EVOK last price ($5.07).
Evoke Pharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $18.00 | $18.00 |
| Last Closing Price | $5.07 | $5.07 | $5.07 |
| Upside/Downside | -100.00% | 255.03% | 255.03% |
In the current month, the average price target of Evoke Pharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Evoke Pharma's last price of $5.07. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 28, 2024 | Laidlaw | Buy | Buy | Hold |
Evoke Pharma's last stock rating was published by Laidlaw on Oct 28, 2024. The company gave EVOK a "Buy" rating, the same as its previous rate.
Evoke Pharma Financial Forecast
Evoke Pharma Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | $1.68M | $1.56M | $1.13M | $810.41K | $796.37K | $832.10K | $461.80K | $418.38K | $360.57K | $930.45K | $236.63K | $90.42K | $23.02K |
| Avg Forecast | $3.08M | $3.36M | $2.98M | $2.14M | $1.63M | $1.26M | $1.10M | $1.00M | $889.00K | $572.00K | $580.00K | $535.00K | $507.00K | $382.00K | $151.00K | $266.00K | $845.00K |
| High Forecast | $3.08M | $3.36M | $2.98M | $2.14M | $1.63M | $1.26M | $1.10M | $1.00M | $889.00K | $572.00K | $580.00K | $535.00K | $507.00K | $382.00K | $151.00K | $266.00K | $845.00K |
| Low Forecast | $3.08M | $3.36M | $2.98M | $2.14M | $1.63M | $1.26M | $1.10M | $1.00M | $889.00K | $572.00K | $580.00K | $535.00K | $507.00K | $382.00K | $151.00K | $266.00K | $845.00K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | 1.03% | 1.24% | 1.03% | 0.81% | 0.90% | 1.45% | 0.80% | 0.78% | 0.71% | 2.44% | 1.57% | 0.34% | 0.03% |
Evoke Pharma's average Quarter revenue forecast for Mar 24 based on 1 analysts is $2.14M, with a low forecast of $2.14M, and a high forecast of $2.14M. EVOK's average Quarter revenue forecast represents a 27.57% increase compared to the company's last Quarter revenue of $1.68M (Dec 23).
Evoke Pharma EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | $-1.89M | $-1.60M | $-1.78M | $-2.12M | $-1.68M | $-1.89M | $-2.11M | $-2.05M | $-1.55M | $-1.84M | $-2.17M | $-2.48M | $-2.21M |
| Avg Forecast | $-1.85M | $-2.01M | $-1.79M | $-1.28M | $-979.20K | $-757.80K | $-657.60K | $-601.80K | $-533.40K | $-343.20K | $-348.00K | $-1.89M | $-304.20K | $-229.20K | $-90.60K | $-1.65M | $-507.00K |
| High Forecast | $-1.85M | $-2.01M | $-1.79M | $-1.28M | $-979.20K | $-757.80K | $-657.60K | $-601.80K | $-533.40K | $-343.20K | $-348.00K | $-1.51M | $-304.20K | $-229.20K | $-90.60K | $-1.32M | $-507.00K |
| Low Forecast | $-1.85M | $-2.01M | $-1.79M | $-1.28M | $-979.20K | $-757.80K | $-657.60K | $-601.80K | $-533.40K | $-343.20K | $-348.00K | $-2.27M | $-304.20K | $-229.20K | $-90.60K | $-1.99M | $-507.00K |
| Surprise % | - | - | - | - | 1.93% | 2.12% | 2.71% | 3.52% | 3.14% | 5.50% | 6.06% | 1.08% | 5.08% | 8.04% | 23.91% | 1.50% | 4.36% |
undefined analysts predict EVOK's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Evoke Pharma's previous annual EBITDA (undefined) of $NaN.
Evoke Pharma Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | $-1.99M | $-1.69M | $-1.87M | $-2.45M | $-1.77M | $-1.99M | $-2.23M | $-2.17M | $-1.67M | $-1.97M | $-2.29M | $-2.61M | $-2.27M |
| Avg Forecast | $-881.93K | $-531.96K | $-1.01M | $-3.53M | $-8.40M | $-10.42M | $-12.26M | $-9.74M | $-8.90M | $-10.80M | $-9.82M | $-2.01M | $-15.71M | $-13.74M | $-15.71M | $-1.74M | $-26.51M |
| High Forecast | $-881.93K | $-531.96K | $-1.01M | $-3.53M | $-8.40M | $-10.42M | $-12.26M | $-9.74M | $-8.90M | $-10.80M | $-9.82M | $-1.60M | $-15.71M | $-13.74M | $-15.71M | $-1.39M | $-26.51M |
| Low Forecast | $-881.93K | $-531.96K | $-1.01M | $-3.53M | $-8.40M | $-10.42M | $-12.26M | $-9.74M | $-8.90M | $-10.80M | $-9.82M | $-2.41M | $-15.71M | $-13.74M | $-15.71M | $-2.08M | $-26.51M |
| Surprise % | - | - | - | - | 0.24% | 0.16% | 0.15% | 0.25% | 0.20% | 0.18% | 0.23% | 1.08% | 0.11% | 0.14% | 0.15% | 1.50% | 0.09% |
Evoke Pharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. EVOK's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Evoke Pharma SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | $3.48M | $3.13M | $2.77M | $2.85M | $2.29M | $2.61M | $2.32M | $2.41M | $1.74M | $2.64M | $2.14M | $2.34M | $2.04M |
| Avg Forecast | $180.07M | $196.07M | $174.00M | $124.83M | $95.29M | $73.74M | $63.99M | $58.56M | $51.91M | $33.40M | $33.86M | $31.24M | $29.60M | $22.30M | $8.82M | $15.53M | $49.34M |
| High Forecast | $180.07M | $196.07M | $174.00M | $124.83M | $95.29M | $73.74M | $63.99M | $58.56M | $51.91M | $33.40M | $33.86M | $31.24M | $29.60M | $22.30M | $8.82M | $15.53M | $49.34M |
| Low Forecast | $180.07M | $196.07M | $174.00M | $124.83M | $95.29M | $73.74M | $63.99M | $58.56M | $51.91M | $33.40M | $33.86M | $31.24M | $29.60M | $22.30M | $8.82M | $15.53M | $49.34M |
| Surprise % | - | - | - | - | 0.04% | 0.04% | 0.04% | 0.05% | 0.04% | 0.08% | 0.07% | 0.08% | 0.06% | 0.12% | 0.24% | 0.15% | 0.04% |
Evoke Pharma's average Quarter SG&A projection for Mar 24 is $124.83M, based on 1 Wall Street analysts, with a range of $124.83M to $124.83M. The forecast indicates a 3484.75% rise compared to EVOK last annual SG&A of $3.48M (Dec 23).
Evoke Pharma EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | $-0.59 | $-0.51 | $-0.56 | $-0.73 | $-0.56 | $-0.60 | $-0.71 | $-0.80 | $-0.62 | $-0.72 | $-0.84 | $-0.96 | $-0.09 |
| Avg Forecast | $-0.63 | $-0.38 | $-0.72 | $-2.52 | $-6.00 | $-7.44 | $-8.76 | $-6.96 | $-6.36 | $-7.92 | $-7.20 | $-5.76 | $-11.52 | $-10.08 | $-11.52 | $-10.08 | $-19.44 |
| High Forecast | $-0.63 | $-0.38 | $-0.72 | $-2.52 | $-6.00 | $-7.44 | $-8.76 | $-6.96 | $-6.36 | $-7.92 | $-7.20 | $-5.76 | $-11.52 | $-10.08 | $-11.52 | $-10.08 | $-19.44 |
| Low Forecast | $-0.63 | $-0.38 | $-0.72 | $-2.52 | $-6.00 | $-7.44 | $-8.76 | $-6.96 | $-6.36 | $-7.92 | $-7.20 | $-5.76 | $-11.52 | $-10.08 | $-11.52 | $-10.08 | $-19.44 |
| Surprise % | - | - | - | - | 0.10% | 0.07% | 0.06% | 0.10% | 0.09% | 0.08% | 0.10% | 0.14% | 0.05% | 0.07% | 0.07% | 0.10% | 0.00% |
According to undefined Wall Street analysts, Evoke Pharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to EVOK previous annual EPS of $NaN (undefined).